Carolina Conceptions Expands its Menu of Reproductive Services with INVOcell
RALEIGH, N.C. and MEDFORD, Mass., Feb. 7, 2018 /PRNewswire/ — INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that Carolina Conceptions, a leading reproductive medicine practice in Raleigh, NC, now includes INVOcell in its menu of reproductive treatments.
INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo, instead of using incubators in a laboratory. The INVO Solution allows women to incubate their own gametes, providing a psychological benefit. Utilizing a mild stimulation protocol, it decreases the number of oocytes required, which may reduce the risk of severe ovarian hyperstimulation (OHSS), reduce the risk of multiple births, and/or reduce the need for embryo cryopreservation and storage. As a lower cost option to traditional IVF, INVOcell expands access to patients who otherwise cannot afford the traditional method or would prefer for a more natural, cultural, or religious appropriate choice.
Co-founded by Dr. Grace Couchman and Dr. Bill Meyer in 2006, Carolina Conceptions is one of the only private practice infertility clinics in the Research Triangle region of North Carolina where every physician is board certified in both OB/GYN and Reproductive Endocrinology and Infertility. Carolina Conceptions also treats patients in Wilmington and Greenville, NC. Carolina Conceptions doctors share more than 70 years of experience in the field of infertility, take a team approach to patient care, and are consistently ranked on the Best Doctors in America list.
Dr. John Park, Reproductive Endocrinologist at Carolina Conceptions said, “Carolina Conceptions is proud to offer INVOcell, the affordable, simple, and more natural form of in-vitro fertilization (“IVF”) to help create families. For many couples struggling with infertility, access to treatment is often not possible. Financial challenges, religious, social or cultural roadblocks can prevent these hopeful parents from realizing their dream to have a baby. INVOcell treatment costs less than half of the average cost of traditional IVF. With over 5,000 pregnancies initiated by our practice since 2006, we believe INVOcell will be a wonderful new addition to our services.”
Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience, commented, “Carolina Conceptions has a long track record of providing reproductive services that initiate successful pregnancies in the Research Triangle area of North Carolina. We firmly believe that INVOcell will be an important new technology that will offer its patients an exciting new option to achieve the pregnancy they so strongly desire. We look forward to working with Carolina Conceptions for many years to come.”
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (“ART”). The INVOcell is the first Intravaginal Culture (“IVC”) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (“IVF”) and Intrauterine Insemination (“IUI”). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504